Integrated Biopharma Inc Financials
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Integrated Biopharma Inc has an operating margin of 3.7%, meaning the company retains $4 of operating profit per $100 of revenue. This below-average margin results in a low score of 19/100, suggesting thin profitability after operating expenses. This is up from 0.5% the prior year.
Integrated Biopharma Inc's revenue grew 8.0% year-over-year to $54.4M, a solid pace of expansion. This earns a growth score of 51/100.
Integrated Biopharma Inc carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.42, Integrated Biopharma Inc holds $4.42 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Integrated Biopharma Inc's free cash flow margin of 3.5% results in a low score of 17/100. Capital expenditures of $191K absorb a large share of operating cash flow.
Integrated Biopharma Inc generates a 4.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 16/100. This is up from 0.6% the prior year.
Integrated Biopharma Inc scores 2.53, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Integrated Biopharma Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Integrated Biopharma Inc generates $2.56 in operating cash flow ($2.1M OCF vs $808K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Integrated Biopharma Inc earns $43.9 in operating income for every $1 of interest expense ($2.0M vs $46K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
This page shows Integrated Biopharma Inc (INBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Integrated Biopharma Inc generated $54.4M in revenue in fiscal year 2025. This represents an increase of 8.0% from the prior year.
Integrated Biopharma Inc's EBITDA was $2.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 319.0% from the prior year.
Integrated Biopharma Inc generated $1.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 380.5% from the prior year.
Integrated Biopharma Inc reported $808K in net income in fiscal year 2025. This represents an increase of 621.4% from the prior year.
Integrated Biopharma Inc earned $0.03 per diluted share (EPS) in fiscal year 2025.
Integrated Biopharma Inc held $3.6M in cash against $0 in long-term debt as of fiscal year 2025.
Integrated Biopharma Inc had 31M shares outstanding in fiscal year 2025. This represents an increase of 3.2% from the prior year.
Integrated Biopharma Inc's gross margin was 10.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.5 percentage points from the prior year.
Integrated Biopharma Inc's operating margin was 3.7% in fiscal year 2025, reflecting core business profitability. This is up 3.2 percentage points from the prior year.
Integrated Biopharma Inc's net profit margin was 1.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.3 percentage points from the prior year.
Integrated Biopharma Inc's ROE was 4.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.4 percentage points from the prior year.
Integrated Biopharma Inc invested $191K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 65.5% from the prior year.
INBP Income Statement
| Metric | Q2'26 | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11K-99.9% | $11.3M-11.1% | $12.7M-9.0% | $13.9M+10.6% | $12.6M-7.4% | $13.6M+3.6% | $13.1M+14.2% | $11.5M |
| Cost of Revenue | $11K-99.9% | $11.3M-3.6% | $11.7M-5.9% | $12.4M+8.3% | $11.4M-6.6% | $12.2M+2.9% | $11.9M+8.3% | $11.0M |
| Gross Profit | $29-99.9% | $29K-97.2% | $1.0M-34.3% | $1.6M+32.5% | $1.2M-14.6% | $1.4M+9.9% | $1.2M+140.0% | $520K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $943-99.9% | $943K+10.2% | $856K+5.4% | $812K-16.2% | $969K+10.0% | $881K-1.3% | $893K-8.1% | $972K |
| Operating Income | $914+100.1% | -$914K-660.7% | $163K-77.9% | $739K+265.8% | $202K-58.8% | $490K+38.0% | $355K+178.5% | -$452K |
| Interest Expense | $40+100.1% | -$40K-21.2% | -$33K-560.0% | -$5K+54.5% | -$11K+21.4% | -$14K-450.0% | $4K+300.0% | -$2K |
| Income Tax | $112+100.1% | -$112K-253.4% | $73K-56.3% | $167K+142.0% | $69K-71.8% | $245K+265.7% | $67K+195.7% | -$70K |
| Net Income | $762+100.1% | -$762K-719.5% | $123K-79.9% | $611K+426.7% | $116K-55.2% | $259K-9.1% | $285K+174.6% | -$382K |
| EPS (Diluted) | $0.03+200.0% | $-0.03 | $0.00-100.0% | $0.02+100.0% | $0.010.0% | $0.010.0% | $0.01+200.0% | $-0.01 |
INBP Balance Sheet
| Metric | Q2'26 | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $24K-99.9% | $23.5M-7.8% | $25.5M-0.5% | $25.7M0.0% | $25.7M-2.0% | $26.2M-2.8% | $26.9M+4.7% | $25.7M |
| Current Assets | $18K-99.9% | $17.8M-9.2% | $19.6M+5.8% | $18.5M+2.2% | $18.2M-0.9% | $18.3M+0.3% | $18.3M+7.0% | $17.1M |
| Cash & Equivalents | $5K-99.9% | $5.3M+12.3% | $4.7M+59.8% | $3.0M+20.3% | $2.5M+8.4% | $2.3M+12.4% | $2.0M+176.0% | $732K |
| Inventory | $8K-99.9% | $8.4M-20.1% | $10.5M+3.9% | $10.1M-8.9% | $11.1M-1.4% | $11.2M+0.5% | $11.2M-8.1% | $12.1M |
| Accounts Receivable | $4K-99.9% | $3.6M-9.8% | $4.0M-21.6% | $5.1M+20.2% | $4.2M-3.6% | $4.4M-7.1% | $4.7M+26.4% | $3.7M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4K-99.9% | $3.8M-25.2% | $5.1M-4.2% | $5.3M-11.1% | $5.9M-10.5% | $6.6M-17.4% | $8.0M+12.2% | $7.2M |
| Current Liabilities | $4K-99.9% | $3.5M-25.7% | $4.8M-4.4% | $5.0M-10.7% | $5.6M-7.5% | $6.0M-13.2% | $6.9M+19.1% | $5.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Total Equity | $20K-99.9% | $19.8M-3.5% | $20.5M+0.5% | $20.4M+3.3% | $19.7M+6.3% | $18.6M-1.9% | $18.9M+1.9% | $18.6M |
| Retained Earnings | $32K+100.1% | -$32.1M-2.4% | -$31.3M-0.2% | -$31.2M+1.9% | -$31.9M+0.4% | -$32.0M+1.6% | -$32.5M+0.9% | -$32.8M |
INBP Cash Flow Statement
| Metric | Q2'26 | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2K-99.7% | $617K-52.6% | $1.3M+111.2% | $616K+206.5% | $201K-69.4% | $657K-60.0% | $1.6M+189.9% | -$1.8M |
| Capital Expenditures | $197-99.2% | $24K-86.1% | $173K+49.1% | $116K+300.0% | $29K-48.2% | $56K-83.8% | $345K+1337.5% | $24K |
| Free Cash Flow | $2K-99.7% | $593K-47.4% | $1.1M+125.6% | $500K+190.7% | $172K-71.4% | $601K-53.7% | $1.3M+170.1% | -$1.9M |
| Investing Cash Flow | $197+100.8% | -$24K+86.1% | -$173K-49.1% | -$116K-300.0% | -$29K+48.2% | -$56K+83.8% | -$345K-1337.5% | -$24K |
| Financing Cash Flow | $22+100.2% | -$11K0.0% | -$11K | $0-100.0% | $18K+357.1% | -$7K+30.0% | -$10K+9.1% | -$11K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
INBP Financial Ratios
| Metric | Q2'26 | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.3%0.0pp | 0.3%-7.8pp | 8.0%-3.1pp | 11.1%+1.8pp | 9.3%-0.8pp | 10.1%+0.6pp | 9.5%+5.0pp | 4.5% |
| Operating Margin | 8.1%+16.2pp | -8.1%-9.4pp | 1.3%-4.0pp | 5.3%+3.7pp | 1.6%-2.0pp | 3.6%+0.9pp | 2.7%+6.6pp | -3.9% |
| Net Margin | 6.8%+13.5pp | -6.8%-7.7pp | 1.0%-3.4pp | 4.4%+3.5pp | 0.9%-1.0pp | 1.9%-0.3pp | 2.2%+5.5pp | -3.3% |
| Return on Equity | 3.9% | N/A | 0.6%-2.4pp | 3.0%+2.4pp | 0.6%-0.8pp | 1.4%-0.1pp | 1.5% | N/A |
| Return on Assets | 3.2%+6.5pp | -3.2%-3.7pp | 0.5%-1.9pp | 2.4%+1.9pp | 0.4%-0.5pp | 1.0%-0.1pp | 1.1%+2.6pp | -1.5% |
| Current Ratio | 5.030.0 | 5.03+0.9 | 4.12+0.4 | 3.72+0.5 | 3.26+0.2 | 3.04+0.4 | 2.63-0.3 | 2.93 |
| Debt-to-Equity | 0.190.0 | 0.19-0.1 | 0.25-0.0 | 0.26-0.0 | 0.30-0.1 | 0.36+0.4 | 0.00-0.4 | 0.39 |
| FCF Margin | 15.3%+10.0pp | 5.3%-3.6pp | 8.9%+5.3pp | 3.6%+2.2pp | 1.4%-3.0pp | 4.4%-5.5pp | 9.9%+25.9pp | -16.1% |
Similar Companies
Frequently Asked Questions
What is Integrated Biopharma Inc's annual revenue?
Integrated Biopharma Inc (INBP) reported $54.4M in total revenue for fiscal year 2025. This represents a 8.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Integrated Biopharma Inc's revenue growing?
Integrated Biopharma Inc (INBP) revenue grew by 8% year-over-year, from $50.3M to $54.4M in fiscal year 2025.
Is Integrated Biopharma Inc profitable?
Yes, Integrated Biopharma Inc (INBP) reported a net income of $808K in fiscal year 2025, with a net profit margin of 1.5%.
What is Integrated Biopharma Inc's earnings per share (EPS)?
Integrated Biopharma Inc (INBP) reported diluted earnings per share of $0.03 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Integrated Biopharma Inc's EBITDA?
Integrated Biopharma Inc (INBP) had EBITDA of $2.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Integrated Biopharma Inc's gross margin?
Integrated Biopharma Inc (INBP) had a gross margin of 10.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Integrated Biopharma Inc's operating margin?
Integrated Biopharma Inc (INBP) had an operating margin of 3.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Integrated Biopharma Inc's net profit margin?
Integrated Biopharma Inc (INBP) had a net profit margin of 1.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Integrated Biopharma Inc's return on equity (ROE)?
Integrated Biopharma Inc (INBP) has a return on equity of 4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Integrated Biopharma Inc's free cash flow?
Integrated Biopharma Inc (INBP) generated $1.9M in free cash flow during fiscal year 2025. This represents a 380.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Integrated Biopharma Inc's operating cash flow?
Integrated Biopharma Inc (INBP) generated $2.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Integrated Biopharma Inc's total assets?
Integrated Biopharma Inc (INBP) had $24.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Integrated Biopharma Inc's capital expenditures?
Integrated Biopharma Inc (INBP) invested $191K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How many shares does Integrated Biopharma Inc have outstanding?
Integrated Biopharma Inc (INBP) had 31M shares outstanding as of fiscal year 2025.
What is Integrated Biopharma Inc's current ratio?
Integrated Biopharma Inc (INBP) had a current ratio of 4.42 as of fiscal year 2025, which is generally considered healthy.
What is Integrated Biopharma Inc's debt-to-equity ratio?
Integrated Biopharma Inc (INBP) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Integrated Biopharma Inc's return on assets (ROA)?
Integrated Biopharma Inc (INBP) had a return on assets of 3.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Integrated Biopharma Inc's Altman Z-Score?
Integrated Biopharma Inc (INBP) has an Altman Z-Score of 2.53, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Integrated Biopharma Inc's Piotroski F-Score?
Integrated Biopharma Inc (INBP) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Integrated Biopharma Inc's earnings high quality?
Integrated Biopharma Inc (INBP) has an earnings quality ratio of 2.56x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Integrated Biopharma Inc cover its interest payments?
Integrated Biopharma Inc (INBP) has an interest coverage ratio of 43.9x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Integrated Biopharma Inc?
Integrated Biopharma Inc (INBP) scores 51 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.